Location
Philadelphia, PA
Start Date
3-5-2023 1:00 PM
End Date
3-5-2023 4:00 PM
Description
Introduction:
Cisplatin is a chemotherapeutic agent used to treat many solid tumors, including ovarian, testicular, bladder, lung, and head and neck tumors. The main side effects associated with the drug include nephrotoxicity, peripheral neurotoxicity, and ototoxicity, with ototoxicity being the dose-limiting effect.
Objective:
The study's overall goal is to determine if cimetidine, a cisplatin uptake inhibitor, has protective effects against cisplatin cytotoxicity on hearing cells with minimal reduction in cisplatin's chemotherapeutic effects on cancer cells. To accomplish this, we want to first determine cisplatin's dose- and time-dependent effects on HEI-OC1 cell viability.
Method:
House Ear Institute-Organ of Corti 1 (HEI-OC1) cells were grown in 6-well plates and treated 24 hours later with cisplatin concentrations of either 0, 10, 50, 100, 150, or 200uM. Cells were imaged using an inverted microscope at 48 hours. The number of dead and alive cells was counted using an automated cell counter at 72 hours.
Results:
Increasing levels of cisplatin concentrations resulted in decreasing numbers of HEI-OC1 cells that were alive and showed changes to cell morphology.
Conclusion:
Cisplatin exerts a negative effect on HEI-OC1 cell viability. We will utilize the above-identified condition to treat cancer and HEI-OC1 cells side by side with and without cimetidine.
Embargo Period
7-5-2023
Included in
Exploring the Applicability of Cisplatin Uptake Inhibitors in the Reduction/Prevention of Ototoxicity
Philadelphia, PA
Introduction:
Cisplatin is a chemotherapeutic agent used to treat many solid tumors, including ovarian, testicular, bladder, lung, and head and neck tumors. The main side effects associated with the drug include nephrotoxicity, peripheral neurotoxicity, and ototoxicity, with ototoxicity being the dose-limiting effect.
Objective:
The study's overall goal is to determine if cimetidine, a cisplatin uptake inhibitor, has protective effects against cisplatin cytotoxicity on hearing cells with minimal reduction in cisplatin's chemotherapeutic effects on cancer cells. To accomplish this, we want to first determine cisplatin's dose- and time-dependent effects on HEI-OC1 cell viability.
Method:
House Ear Institute-Organ of Corti 1 (HEI-OC1) cells were grown in 6-well plates and treated 24 hours later with cisplatin concentrations of either 0, 10, 50, 100, 150, or 200uM. Cells were imaged using an inverted microscope at 48 hours. The number of dead and alive cells was counted using an automated cell counter at 72 hours.
Results:
Increasing levels of cisplatin concentrations resulted in decreasing numbers of HEI-OC1 cells that were alive and showed changes to cell morphology.
Conclusion:
Cisplatin exerts a negative effect on HEI-OC1 cell viability. We will utilize the above-identified condition to treat cancer and HEI-OC1 cells side by side with and without cimetidine.